摘要
目的:观察磷酸肌酸钠治疗扩张型心肌病伴心功能不全患者的疗效。方法:将103例扩张型心肌病心功能不全的患者随机为两组,对照组给予血管紧张素转换酶抑制剂或血管紧张素II受体拮抗剂,利尿剂,β受体阻滞剂(无禁忌证),强心剂,血管扩张剂等基础抗心衰治疗,试药组在此基础上给予磷酸肌酸钠。观察治疗前和治疗后患者的心功能分级、左室收缩功能相关参数的变化,并观察药物不良反应。结果:两组患者经治疗后临床症状均有好转,但是试药组心悸、呼吸困难、水肿等改善率,脑钠尿肽水平的下降、左室射血分数的增加显著优于对照组(P<0.05)。结论:磷酸肌酸钠可以安全、有效地改善扩张型心肌病心功能不全患者的临床症状和心功能指标。
AIM：To explore the possible mechanism and to evaluate the clinical effects of sodium phosphocreatine in patients with dilated cardiomyopathy （DCM） with heart failure. METHODS： A cohort of 103 cases with DCM with heart failure was randomized into two groups. The control group was given ACEI or AEB agents, diuretics, β blockers （without contraindications）, cardiac stimulant, and vasodilator agentbased anticardiac insufficiency treatment, whereas the therapy group was administered the same regimen plus sodium phosphocreatine. Changes in functional heart classifications and left ventricular diastolic function parameters and adverse drug reactions were observed before and after treatment. RESULTS： Clinical symptoms in both groups were alleviated after treatment, but clinical symptoms and signs such as shortness of breath, palpitations, and edema in the therapy group were better improved than in the control group （P〈005）. The decrease in probrain natriuretic peptide （BNP） levels and increase in left ventricular ejection scores in the therapy group were also more obvious （P〈0.05）. CONCLUSION： Sodium phosphocreatine can safely and effectively alleviate clinical symptoms and improve cardiac functions in patients with dilated cardiomyopathy with cardiac insufficiency.
出处
《心脏杂志》
CAS
2013年第6期689-691,共3页
Chinese Heart Journal
关键词
磷酸肌酸钠
扩张型心肌病
心功能不全
脑钠尿肽
sodium phosphocreatine
dilated cardiomyopathy
heart failure
pro-brain natriuretic peptide
